We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+13.04%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$587M
AUM Growth
-$222M
Cap. Flow
-$5.15B
Cap. Flow %
-877.82%
Top 10 Hldgs %
35.65%
Holding
170
New
43
Increased
23
Reduced
46
Closed
45

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$19.7M
2
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$16.8M
3
BIIB icon
Biogen
BIIB
+$12.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$8.46M
5
ORA icon
Ormat Technologies
ORA
+$7.92M

Top Sells

Rank Stock Value
1
ISRL
Isramco Inc
ISRL
+$4.99B
2
MRK icon
Merck
MRK
+$24.8M
3
ABBV icon
AbbVie
ABBV
+$23.3M
4
AGN
Allergan Inc
AGN
+$23M
5
JNJ icon
Johnson & Johnson
JNJ
+$22.1M

Sector Composition

Rank Sector Weight
1 Healthcare 63.04%
2 Technology 5.1%
3 Industrials 3.71%
4 Energy 1.9%
5 Consumer Discretionary 1.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QURE icon
76
uniQure
QURE
$3.03B
$2.49M 0.42%
+168,415
New +$2.06M
BCOM
77
DELISTED
B Communications Ltd
BCOM
$2.42M 0.41%
134,174
-187,257
-58% -$3.65M
CEMP
78
DELISTED
Cempra, Inc.
CEMP
$2.35M 0.4%
+100,000
New +$1.49M
ELDN icon
79
Eledon Pharmaceuticals
ELDN
$261M
$2.27M 0.39%
950
-470
-33% -$1.12M
LRMR icon
80
Larimar Therapeutics
LRMR
$397M
$2.22M 0.38%
6,008
-2,084
-26% -$537K
CSX icon
81
CSX Corp
CSX
$93.4B
$2.16M 0.37%
178,944
-240,081
-57% -$2.81M
ORA icon
82
Ormat Technologies
ORA
$6B
$2.13M 0.36%
309,000
+289,111
+1,454% +$7.92M
IMUX icon
83
Immunic
IMUX
$190M
$2.04M 0.35%
+205
New +$1.58M
ENTA icon
84
Enanta Pharmaceuticals
ENTA
$366M
$2.03M 0.35%
+40,000
New +$1.79M
NICE icon
85
Nice
NICE
$5.79B
$2.01M 0.34%
39,652
-24,890
-39% -$1.12M
CNCE
86
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$2M 0.34%
150,000
+127,300
+561% +$1.64M
PTLA
87
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$1.98M 0.34%
+70,000
New +$1.95M
ELLO icon
88
Ellomay Capital Ltd
ELLO
$270M
$1.98M 0.34%
203,778
+12,576
+7% +$119K
SBUX icon
89
Starbucks
SBUX
$120B
$1.97M 0.34%
+48,000
New +$1.87M
LJPC
90
DELISTED
La Jolla Pharmaceutical Company
LJPC
$1.85M 0.32%
100,230
-123,100
-55% -$1.46M
TEVA icon
91
CALL
Teva Pharmaceuticals
TEVA
$40.8B
$1.8M 0.31%
464,200
+89,000
+24% +$4.96M
CTIC
92
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$1.77M 0.3%
+75,000
New +$1.73M
ICPT
93
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.56M 0.27%
10,000
-4,565
-31% -$843K
CKP
94
DELISTED
CHECKPOINT SYSTEMS INC
CKP
$1.55M 0.26%
+19,688
New +$254K
ACHN
95
DELISTED
Achillion Pharmaceuticals
ACHN
$1.54M 0.26%
+125,538
New +$1.53M
BHC icon
96
CALL
Bausch Health
BHC
$2.57B
$1.4M 0.24%
97,200
– –
AMGN icon
97
Amgen
AMGN
$208B
$1.36M 0.23%
8,550
-40,000
-82% -$6.23M
PRTA icon
98
Prothena Corp
PRTA
$425M
$1.3M 0.22%
62,632
+32,725
+109% +$683K
WIX icon
99
WIX.com
WIX
$2.3B
$1.24M 0.21%
+59,108
New +$1.13M
RXDX
100
DELISTED
Ignyta, Inc.
RXDX
$1.23M 0.21%
179,055
-20,000
-10% -$136K
2 3
4
5 6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2014 Portfolio in Review

As of Q4 2014, Sphera Funds Management held 170 positions worth $587M, down 27% from $809M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Sphera Funds Management withdrew a net $5.15B in Q4 2014, closing 45 positions and reducing 46 holdings. Its most notable exit was Merck, an estimated $24.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 57% a quarter earlier, followed by Technology and Industrials.

Against the trend, Sphera Funds Management opened a new position in Gilead Sciences worth $17.9M.

  • Sphera Funds Management's largest Q4 2014 buy was Gilead Sciences: 190,000 shares worth $17.9M.
  • Sphera Funds Management added most to SALIX PHARMACEUTICALS LTD DEL in Q4 2014, an estimated $16.8M increase.
  • Sphera Funds Management's biggest Q4 2014 reduction was Isramco Inc, cutting an estimated $4.99B.
  • Sphera Funds Management fully exited Merck in Q4 2014, selling an estimated $24.8M.
  • Sphera Funds Management's ten largest holdings make up 36% of its $587M portfolio in Q4 2014.
  • Sphera Funds Management opened 43 new positions and closed 45 in Q4 2014.
  • Sphera Funds Management's portfolio value fell 27% quarter-over-quarter to $587M.

Based on Sphera Funds Management's 13F filing for Q4 2014, filed 12 Feb 2015.